NPR3 and metastatic colorectal cancer: In this phase 1 nonrandomized clinical trial of 15 patients with metastatic colorectal cancer (mCRC), the safety and preliminary antitumor activity of guanylate cyclase-C (GCC19) CART, a novel chimeric antigen receptor technology, were evaluated.